Disposition of MDMA and Metabolites in Human Sweat Following Controlled MDMA Administration

Clinical Chemistry

Volumn 55, Issue 3, 2009, Pages 454-462

  Barnes, Allan J ^a,c   De Martinis, Bruno S ^b   Gorelick, David A ^a   Goodwin, Robert S ^a   Kolbrich, Erin A ^a,c   Huestis, Marilyn A ^a,d  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Medical Examiners Office   (United States)

^d Biomedical Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 O METHYL ALPHA METHYLDOPAMINE; 3,4 METHYLENEDIOXYAMPHETAMINE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 HYDROXY 3 METHOXYMETHAMPHETAMINE; AMPHETAMINE; DRUG METABOLITE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL RESEARCH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DATA BASE; DRUG USE; FEMALE; HISTORY; HUMAN; MALE; MASS FRAGMENTOGRAPHY; MENTAL HEALTH SERVICE; MONITORING; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; SOLID PHASE EXTRACTION; SWEAT; SWEAT TEST; VOLUNTEER; ADOLESCENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; METABOLISM; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; ADULT; FEMALE; HUMANS; MALE; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; SWEAT;

EID: 62149142830     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2008.117093     Document Type: Article

References (33)

1. Nelson AE, Ho KK. Abuse of growth hormone by athletes. Nat Clin Pract Endocrinol Metab 2007; 3:198-9.
2. Rigamonti AE, Cella SG, Marazzi N, Di Luigi L, Sartorio A, Muller EE. Growth hormone abuse: methods of detection. Trends Endocrinol Metab 2005;16:160-6.
3. Berggren A, Ehrnborg C, Rosen T, Ellegard L, Bengtsson BA, Caidahl K. Short-term administra- tion of supraphysiological recombinant human growth hormone (GH) does not increase maxi- mum endurance exercise capacity in healthy, ac- tive young men and women with normal GH- insulin-like growth factor I axes. J Clin Endocrinol Metab 2005;90:3268-73.
4. Dean H. Does exogenous growth hormone im- prove athletic performance? Clin J Sport Med 2002;12:250-3.
5. Rennie MJ. Claims for the anabolic effects of growth hormone: a case of the emperor's new clothes? Br J Sports Med 2003;37:100-5.
6. World Anti-Doping Agency (WADA). The 2008 prohibited list: international standard. http://www.wada-org/en/prohibitedlist.ch2 (Accessed June 2008).
7. Bidlingmaier M, Strasburger CJ. Technology insight: detecting growth hormone abuse in ath- letes. Nat Clin Pract Endocrinol Metab 2007;3: 769-77.
8. McHugh CM, Park RT, Sonksen PH, Holt RI. Chal- lenges in detecting the abuse of growth hormone in sport. Clin Chem 2005;51:1587-93.
9. Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Baillieres Best Pract Res Clin Endo- crinol Metab 2000;14:99-109.
10. Healy ML, Russell-Jones D. Growth hormone and sport: abuse, potential benefits, and difficulties in detection. Br J Sports Med 1997;31:267-8.
11. Powrie JK, Bassett EE, Rosen T, Jorgensen JO, Napoli R, Sacca L, et al. Detection of growth hormone abuse in sport. Growth Horm IGF Res 2007;17:220-6.
12. Ehrnborg C, Lange KH, Dall R, Christiansen JS, Lundberg PA, Baxter RC, et al. The growth hor- mone/insulin-like growth factor-I axis hormones and bone markers in elite athletes in response to a maximum exercise test. J Clin Endocrinol Metab 2003;88:394-401.
13. Wallace JD, Cuneo RC, Lundberg PA, Rosen T, Jorgensen JO, Longobardi S, et al. Responses of markers of bone and collagen turnover to exer- cise, growth hormone (GH) administration, and GH withdrawal in trained adult males. J Clin Endocrinol Metab 2000;85:124-33.
14. Healy ML, Dall R, Gibney J, Bassett E, Ehrnborg C, Pentecost C, et al. Toward the development of a test for growth hormone (GH) abuse: a study of extreme physiological ranges of GH-dependent markers in 813 elite athletes in the postcompe- tition setting. J Clin Endocrinol Metab 2005;90: 641-9.
15. Nelson AE, Howe CJ, Nguyen TV, Leung KC, Trout GJ, Seibel MJ, et al. Influence of demographic factors and sport type on growth hormone- responsive markers in elite athletes. J Clin Endo- crinol Metab 2006;91:4424-32.
16. Nguyen TV, Nelson AE, Howe CJ, Seibel MJ, Baxter RC, Handelsman DJ, et al. Within-subject variability and analytic imprecision of insulinlike growth factor axis and collagen markers: impli- cations for clinical diagnosis and doping tests. Clin Chem 2008;54:1268-76.
17. Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hor- mone. Lancet 1999;353:895.
18. Baumann G. Growth hormone heterogeneity in human pituitary and plasma. Horm Res 1999;51 Suppl 1:2-6.
19. De Palo EF, De Filippis V, Gatti R, Spinella P. Growth hormone isoforms and segments/fragments: molecular structure and laboratory measurement. Clin Chim Acta 2006;364:67-76.
20. Popii V, Baumann G. Laboratory measurement of growth hormone. Clin Chim Acta 2004;350:1-16.
21. World Anti-Doping Agency (WADA). International standard for laboratories. Version 4.0. http://www.wada-ama.org/rtecontent/document/lab-aug-04.pdf (Accessed June 2008).
22. Wu Z, Bidlingmaier M, Strasburger CJ. Develop- ment of human growth hormone (hGH) isoform specific antibodies and their use in a possible test to detect hGH-doping in sports [Abstract]. Endo 2002 programme and abstracts book; 2002 Jun 19-22; San Francisco. Bethesda (MD): The Endo- crine Society Press; 2002. p. 615. Abstract nr P3-527.
23. Saugy M, Robinson N, Saudan C, Baume N, Avois L, Mangin P. Human growth hormone doping in sport. Br J Sports Med 2006;40 Suppl 1:i35-9.
24. Keller A, Wu Z, Kratzsch J, Keller E, Blum WF, Kniess A, et al. Pharmacokinetics and pharmaco- dynamics of GH: dependence on route and dos- age of administration. Eur J Endocrinol 2007;156: 647-53.
25. Bidlingmaier M, Wu Z, Strasburger CJ. Problems with GH doping in sports. J Endocrinol Invest 2003;26:924-31.
26. Wieringa GE, Trainer PJ. Commentary: Harmoniz-452 Clinical Chemistry 55:3 (2009) Detection of GH Doping by Differential Immunoassaysing growth hormone measurements: learning les- sons for the future. J Clin Endocrinol Metab 2007; 92:2874-5.
27. Pokrajac A, Wark G, Ellis AR, Wear J, Wieringa GE, Trainer PJ. Variation in GH and IGF-I assays limits the applicability of international consensus criteria to local practice. Clin Endocrinol (Oxf) 2007;67:65-70.
28. Frankenne F, Scippo ML, Van Beeumen J, Igout A, Hennen G. Identification of placental human growth hormone as the growth hormone-V gene expression product. J Clin Endocrinol Metab 1990;71:15-8.
29. Wu Z, Bidlingmaier M, Friess SC, Kirk SE, Buch- inger P, Schiessl B, Strasburger CJ. A new noniso- topic, highly sensitive assay for the measurement of human placental growth hormone: develop- ment and clinical implications. J Clin Endocrinol Metab 2003;88:804-11.
30. Hansen TK, Fisker S, Hansen B, Sorensen HH, Christiansen JS, Jorgensen JO, Orskov H. Impact of GHBP interference on estimates of GH and GH pharmacokinetics. Clin Endocrinol (Oxf) 2002;57: 779-86.
31. Jansson C, Boguszewski C, Rosberg S, Carlsson L, Albertsson-Wikland K. Growth hormone (GH) assays: influence of standard preparations, GH isoforms, assay characteristics, and GH-binding protein. Clin Chem 1997;43:950-6.
32. Leung KC, Howe C, Gui LY, Trout G, Veldhuis JD, Ho KK. Physiological and pharmacological regu- lation of 20-kDa growth hormone. Am J Physiol Endocrinol Metab 2002;283:E836-43.
33. Veldhuis JD, Bidlingmaier M, Anderson SM, Evans WS, Wu Z, Strasburger CJ. Impact of experimental blockade of peripheral growth hormone (GH) re- ceptors on the kinetics of endogenous and exog- enous GH removal in healthy women and men. J Clin Endocrinol Metab 2002;87:5737-45.